56 Identification and Prioritization of Human Endogenous Retrovirus–Derived Antigens for mRNA Vaccine Development in Renal Cell Carcinoma
Abstract Background Immune checkpoint inhibitors improve outcomes in clear cell renal cell carcinoma (ccRCC), yet most patients do not achieve durable responses due in part to insufficient tumor antigenicity. While neoantigen vaccines have shown promising early-phase results in ccRCC, their patient-specific design limi...